

Amplify Treatments, Testing and Advancements ETF

As of 3/31/24

FUND FACTS

Ticker	GERM™
CUSIP	032108581
Inception Date	6/17/2020
Primary Exchange	NYSE ARCA
Number of Holdings	54
Expense Ratio	0.68%

INDEX

Index Name	Prime Treatments, Testing and Advancements Index
Index Ticker	PGERMN
Weighting	Modified Equal
Rebalance	Quarterly
Website	primeindexes.com

MARKET CAPITALIZATION

Large Cap (> \$10B)	41.32%
Mid Cap (\$2B - \$10B)	20.39%
Small Cap (< \$2B)	38.29%

ABOUT THE FUND

GERM™ seeks investment results that generally correlate (before fees and expenses) to the total return performance of the Prime Treatments, Testing and Advancements Index. GERM holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.

REASONS TO INVEST

- Healthcare advancements have had the most impact in combating different diseases, with vaccines, therapies and testing being at the forefront of those developments.
- Global biotechnology market was valued at \$1.55 trillion in 2023 and is projected to grow at a CAGR of 13.96% from 2024 to 2030.¹
- There are over 20 combined epidemic and pandemic-prone diseases affecting the world today.²
- More than 50 variants of the coronavirus have been identified.³

TOP 10 HOLDINGS

TICKER	COMPANY	% WT.	TICKER	COMPANY	% WT.
MRNA	Moderna	6.83%	IBRX	ImmunityBio	4.48%
DGX	Quest Diagnostics	6.30%	BIO	Bio-Rad Laboratories	4.18%
BNTX	BioNTech SE	6.13%	QDEL	QuidelOrtho	4.14%
LH	Laboratory Corp of America Hldgs	5.98%	IMCR	Immunocore Hldgs	3.81%
ALNY	Alnylam Pharmaceuticals	5.85%	DVAX	Dynavax Technologies	3.76%


Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

PERFORMANCE

	CUMULATIVE (%)			ANNUALIZED (%)			
	1 MO.	YTD	SINCE INCEPTION	1 YR.	3 YR.	5 YR.	SINCE INCEPTION
NAV	0.79%	-5.63%	-23.56%	-11.05%	-18.81%	N/A	-6.85%
Closing Price	0.25%	-5.60%	-23.92%	-8.98%	-19.00%	N/A	-6.97%
Prime Treatments, Testing and Advancements Index	0.69%	-5.66%	-24.00%	-10.41%	-18.86%	N/A	-6.99%

Fund inception date: 06/17/2020. The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end visit AmplifyETFs.com/GERM. Brokerage commissions will reduce returns. A fund's NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price or market price is the most recent price at which the fund was traded. Indexes are unmanaged and it's not possible to invest directly in an index. The Prime Treatments, Testing, and Advancements Index tracks the performance of companies engaged in R&D, vaccines, therapies, and testing technologies.

COUNTRY ALLOCATION



- United States (81.84%)
- Germany (7.96%)
- United Kingdom (5.55%)
- China (3.03%)
- France (0.84%)
- Japan (0.78%)

Carefully consider the Fund's investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund's statutory and summary prospectuses, which may be obtained at amplifyetfs.com. Read the prospectus carefully before investing.

Prior to 1/29/24, the Amplify Treatments, Testing and Advancements ETF was formerly the ETFMG Treatments, Testing and Advancements ETF.

Investing involves risk, including loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Narrowly focused investments typically exhibit higher volatility. Treatment Companies and Testing Companies are involved in discovering, developing and commercializing novel drugs or tests with significant

market potential. These companies face challenges including pre-clinical testing and clinical trial stages of development. Clinical trials may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than anticipated. Such companies may be dependent on their ability to secure significant funding for research, development, and commercialization of therapeutics, vaccines, tests, and other health care products or services. If there are delays in obtaining required regulatory and marketing approvals for products, the ability of such companies to generate revenue may be materially impaired. If regulatory approval is obtained, products will still remain subject to regulatory scrutiny with regulatory authorities having the ability to impose significant restrictions on the indicated uses or marketing. Lastly, even if a licensed product is achieved, such companies may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain

management, or shipping.

Amplify Investments LLC is the Investment Adviser to the Fund, and Toroso Investments, LLC serves as the Investment Sub-Adviser. Amplify ETFs are distributed by Foreside Fund Services, LLC.

¹Biotechnology Market Size, Share & Growth Report, 2030 (grandviewresearch.com) CAGR is the compound annual growth rate.

²World Health Organization: <http://www.emro.who.int/pandemic-epidemic-diseases/health-topics/related-health-topics.html>

³COVID Variants and Strains (webmd.com)

Not FDIC Insured | No Bank Guarantee | May Lose Value